The PRIME-ROSE consortium gathered for its mid-term meeting on 29-30 April 2026 in the Centre Léon Bérard in Lyon, bringing together project partners and stakeholders to review progress and align on next steps.

The meeting provided a comprehensive overview of ongoing activities across PRIME-ROSE work packages, highlighting key achievements and upcoming priorities. The event was held alongside the Joint Action on Personalised Cancer Medicine (JA PCM) WP8 Leadership Meeting.

Day one focused on key scientific and methodological developments across PRIME-ROSE work packages. Sessions covered the publication pipeline, the data sharing platform (WP1), and the use of real-world data for external control arms (WP2). Further discussions addressed off-label drug implementation pathways, health technology assessment and reimbursement, and social innovation aspects.

Day two continued with forward-looking discussions and strategic alignment. Topics included expansion cohorts, the drug strategy for PRIME-ROSE, and the statistical analysis plan. Partners also discussed internal collaboration and data sharing practices, national implementation pathways, and project-wide management updates.

The meeting offered an important opportunity for in-person exchange, strengthening collaboration across partners and fostering synergies with the broader JA PCM initiative. Participants also had the opportunity to visit the hosting facilities, further supporting knowledge exchange and future cooperation.

The PRIME-ROSE consortium continues to make steady progress towards enabling more effective and evidence-based approaches in personalised cancer medicine across Europe.

‍